Dynamic Change of Focal Fatty Sparing in Non-Alcoholic Fatty Liver Disease after Treatment with Sitagliptin
2016
Abstrakt
In our patient, we found new FFS in previously diffuse homogeneous fatty liver after sitagliptin administration. We hypothesize that this finding results from "demasking" of FFS in diffuse homogeneous hepatic steatosis in an individual likely to have aberrant venous liver circulation.
Since treatment with sitagliptin is known to decrease fat content in hepatocytes and that the effect can occur rapidly in areas with diminished portal perfusion, i. e., with diminished nutrients supplies from the intestines.